GSK shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced ...

GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its ...

GSK has agreed to pay up to $2.2 billion to resolve ... The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S., most of which had been ...

GSK said late Wednesday that it agreed to settle a vast majority of lawsuits concerning its discontinued heartburn medicine Zantac. "GSK Shares Climb on $2.2 Bln Zantac Lawsuit Settlement," at 0754 ...

GSK topped the Stoxx Europe 600 index after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands ...

GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 ...

Oct 8 (Reuters) - GSK (GSK.L), opens new tab said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients ...

GlaxoSmithKline Pharma, celebrating 100 years in India, is shifting to a specialty-focused model by entering the oncology market and expanding its preventive healthcare through adult vaccines.

Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US as Millions Fewer People Line Up By Michael Erman (Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after ...

The past few years have seen a hot new trend in Halloween decorations — giant skeletons. Some soar several feet tall. Others climb from a coffin, creep in a graveyard, or sit on a porch swing. But ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...